Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Sanjivani Paranterals's Revenue for the
three
months ended in Jun. 2026 was ₹238.4 Mil. Sanjivani Paranterals's average Accounts Receivable for the
three
months ended in Jun. 2026 was ₹154.3 Mil.
Hence, Sanjivani Paranterals's Receivables Turnover for the
three
months ended in Jun. 2026 was 1.55.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Sanjivani Paranterals Receivables Turnover Related Terms
Sanjivani Paranterals Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Sanjivani Paranterals's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:531569 vs ZTS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sanjivani Paranterals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanjivani Paranterals Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanjivani Paranterals's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Sanjivani Paranterals's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanjivani Paranterals (BOM:531569) has a Receivables Turnover of 1.55 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Sanjivani Paranterals and its competitors. According to the industry distribution chart, Sanjivani Paranterals ranks #489 out of 947 companies in the Drug Manufacturers industry, placing it in the top 51.6%.
Is Sanjivani Paranterals' Receivables Turnover too high?
Sanjivani Paranterals' current Receivables Turnover is 1.55. The Drug Manufacturers industry median Receivables Turnover is 5.08. Sanjivani Paranterals' value of 1.55 is 69.5% below this industry median. Based on the distribution chart, Sanjivani Paranterals ranks #489 out of 947 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sanjivani Paranterals has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sanjivani Paranterals' Receivables Turnover compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sanjivani Paranterals ranks #489 out of 947 companies for Receivables Turnover. This places Sanjivani Paranterals in the lower half of its industry. The industry median Receivables Turnover is 5.08. Sanjivani Paranterals' value of 1.55 is 69.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.08, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanjivani Paranterals's current Receivables Turnover of 1.55 is 69.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Sanjivani Paranterals and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanjivani Paranterals's current Receivables Turnover is 1.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanjivani Paranterals stock overvalued right now?
Based on GuruFocus' analysis, Sanjivani Paranterals (BOM:531569) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹242.92, compared to a current price of ₹190.45 — trading 21.6% below its estimated fair value. The current Receivables Turnover is 1.55 and 69.5% below the Drug Manufacturers industry median of 5.08. Sanjivani Paranterals' overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Sanjivani Paranterals (BOM:531569), the current Receivables Turnover is 1.55 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanjivani Paranterals (BOM:531569) Overvalued in 2026?
Based on GuruFocus' analysis, Sanjivani Paranterals stock appears to be undervalued.
The current stock price of ₹190.45 is trading 21.6% below its estimated GF Value™ of ₹242.92.
GuruFocus considers Sanjivani Paranterals to be Modestly Undervalued.
Key valuation signals for BOM:531569:
Receivables Turnover: 1.55
GF Value™: ₹242.92 vs. price of ₹190.45 (21.6% below fair value)
Industry Position: 69.5% below the Drug Manufacturers median (#489 of 947)
No single metric tells the full story. See the BOM:531569 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanjivani Paranterals Ltd is a pharmaceutical company principally engaged in providing pharmaceutical products and services. The company's main product range includes oral solids and small-volume parenteral and sterile powder formulations. The products offered by the company are anti-biotic, anti-emetic, anti-tuberculosis, anti-diabetic, anti-malarial, anti-fungal, calcium and vitamin, multivitamin, sedative, cardiovascular, anti-gout, and others. The company also provides Liquid Injection, Dry powder Injection, Capsules, Drops, and others. The firm sells its products in India and internationally.
73GF Score
Get the complete analysis for BOM:531569
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531569 has been successfully added to your 
